Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011)
| العنوان: | Small-molecule BACE1 inhibitors: a patent literature review (2006 – 2011) |
|---|---|
| المؤلفون: | Gary Probst, Ying-Zi Xu |
| المصدر: | Expert Opinion on Therapeutic Patents. 22:511-540 |
| بيانات النشر: | Informa UK Limited, 2012. |
| سنة النشر: | 2012 |
| مصطلحات موضوعية: | Pathology, medicine.medical_specialty, Aspartyl Proteinases, Patent literature, Disease, Bioinformatics, Patents as Topic, Structure-Activity Relationship, Alzheimer Disease, mental disorders, Drug Discovery, Animals, Aspartic Acid Endopeptidases, Humans, Medicine, Protease Inhibitors, Pharmacology, Amyloid beta-Peptides, Molecular Structure, business.industry, Neurodegeneration, Brain, General Medicine, Legislation, Drug, medicine.disease, Small molecule, Biochemistry of Alzheimer's disease, Drug Design, Amyloid Precursor Protein Secretases, business |
| الوصف: | Alzheimer's disease is a devastating neurodegenerative disorder for which no disease-modifying therapy exists. The amyloid hypothesis, which implicates Aβ as the toxin initiating a biological cascade leading to neurodegeneration, is the most prominent theory concerning the underlying cause of the disease. BACE1 is one of two aspartyl proteinases that generate Aβ, thus inhibition of BACE1 has the potential to ameliorate the progression of Alzheimer's disease by abating the production of Aβ.This review chronicles small-molecule BACE1 inhibitors as described in the patent literature between 2006 and 2011 and their potential use as disease-modifying treatments for Alzheimer's disease. Over the past half a dozen years, numerous BACE1 inhibitors have been published in the patent applications, but often these contain a paltry amount of pertinent biological data (e.g. potency, selectivity, and efficacy). Fortunately, numerous relevant publications containing important data have appeared in the journal literature during this period. The goal in this effort was to create an amalgam of the two records to add value to this review.The pharmaceutical industry has made tremendous progress in the development of small-molecule BACE1 inhibitors that lower Aβ in the central nervous system. Assuming the amyloid hypothesis is veracious, we anticipate a disease-modifying therapy to combat Alzheimer's disease is near. |
| تدمد: | 1744-7674 1354-3776 |
| DOI: | 10.1517/13543776.2012.681302 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c138913ade3c5475c822ba1d99c9af https://doi.org/10.1517/13543776.2012.681302 |
| رقم الانضمام: | edsair.doi.dedup.....77c138913ade3c5475c822ba1d99c9af |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447674 13543776 |
|---|---|
| DOI: | 10.1517/13543776.2012.681302 |